Semaglutide benefits: what the evidence shows. - Reddit

What does semaglutide do in the body?

Semaglutide is a GLP-1 receptor agonist — a synthetic analog of glucagon-like peptide-1, a hormone the body naturally releases after eating. GLP-1 regulates appetite signaling in the hypothalamus, slows gastric emptying to extend satiety, and supports glucose-dependent insulin secretion.

In a clinical context, semaglutide amplifies all three of these natural mechanisms at levels that produce measurable, sustained effects on food intake, body weight, and metabolic markers. It is not a stimulant, an appetite suppressant in the traditional pharmacological sense, or a metabolic accelerant — it works by making the body’s own regulatory signals louder and longer-lasting.

What does the evidence show for semaglutide and weight management?

The most extensively documented semaglutide benefit is support for substantial, sustained weight reduction. The STEP (Semaglutide Treatment Effect in People with obesity) trial program enrolled over 4,500 participants across four major studies.

In STEP 1 — the landmark trial in adults with overweight or obesity without diabetes — participants receiving weekly semaglutide 2.4 mg lost an average of14.9% of their body weight over 68 weeks. The placebo group averaged 2.4%body weight reduction. Approximately 70% of participants on semaglutide achieved at least 10% body weight reduction, and about one-third achieved20% or more.

These are outcomes that had not previously been achievable with any approved weight management medication. Prior drugs in this class typically produced 5–8% body weight reduction. Semaglutide represented a meaningful step change.

It is important to be precise about what this means: the clinical trials measured body weight reduction in controlled research populations with specific inclusion criteria. Individual results vary based on dose achieved, adherence, baseline metabolic state, dietary habits, and activity levels. No specific outcome can be promised to an individual patient.

What metabolic markers improve on semaglutide?

Weight reduction is accompanied by a constellation of metabolic improvements consistently observed across the STEP trials:

• Blood pressure: Systolic blood pressure decreased by an average of 6–7 mmHg in participants on semaglutide 2.4 mg, likely driven by weight reduction and direct vascular effects.
• Lipid profiles: Reductions in triglycerides and improvements in HDL cholesterol were observed, consistent with the metabolic effects of weight reduction and GLP-1 signaling.
• Waist circumference: Visceral fat — the metabolically active fat stored around the abdominal organs — is specifically reduced. Waist circumference decreased by an average of 13–14 cm in STEP 1.
• Inflammation markers: C-reactive protein (CRP), a systemic inflammation marker, declined with semaglutide use in several studies — a finding with implications beyond weight management.

These metabolic changes are partly caused by weight reduction and partly independent of it — GLP-1 receptors are expressed in cardiac, vascular, and hepatic tissue, and direct receptor effects appear to contribute to some of the metabolic benefits observed.

What did the SELECT trial show about cardiovascular outcomes?

In 2023, the SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) published results that substantially broadened the clinical case for semaglutide.

SELECT enrolled 17,604 adults with overweight or obesity who had pre-existing cardiovascular disease but no diabetes diagnosis. Participants received semaglutide 2.4 mg weekly or placebo for a median of 34 months. The primary endpoint was major adverse cardiovascular events (MACE): cardiovascular death, non-fatal heart attack, or non-fatal stroke.

Semaglutide reduced MACE by 20% relative to placebo. This was a statistically significant, clinically meaningful reduction in hard cardiovascular endpoints in a high-risk population. The finding extended semaglutide’s evidence base from weight management into cardiovascular risk reduction — two distinct benefit categories in the same compound.

It is critical to note: SELECT enrolled patients with established cardiovascular disease. Extrapolating cardiovascular event reduction to otherwise-healthy adults without CVD history is not supported by this data. Discuss your specific risk profile with your clinician.

How long do semaglutide’s benefits last? What happens when you stop?

One of the most practically important semaglutide benefit questions is: how long do the benefits last?

The STEP 4 trial addressed discontinuation directly. After 20 weeks on semaglutide — during which participants lost an average of 10.6% of body weight — half the cohort was switched to placebo while the other half continued. Over the following 48 weeks, the placebo group regained about two-thirds of their lost weight; the continuation group maintained most of their reduction.

This data suggests semaglutide’s benefits are tied to ongoing use. This is consistent with how GLP-1 signaling works — it is pharmacological support for appetite regulation, not a permanent metabolic reset. Patients and clinicians should plan for this reality at the outset: semaglutide is often most effective when approached as a long-term or indefinite protocol rather than a short course.

What does the 503A context mean for compounded semaglutide?

The clinical evidence summarized in this article was generated using pharmaceutical-grade semaglutide in controlled trials. Compounded semaglutide, prepared by licensed 503A compounding pharmacies in the United States, is a different regulatory category — it is individualized patient medication prepared pursuant to a valid prescription, not an FDA-approved drug.

Compounded semaglutide is not FDA-approved. It should never be described as “the same as Ozempic” or “the same as Wegovy” — those are branded pharmaceutical products with their own manufacturing standards and approval histories. Compounded preparations are legally and regulatorily distinct.

What compounded semaglutide can offer, when prepared by a licensed 503A pharmacy, is access to the same active molecule — semaglutide — at a price point that is more accessible for many patients, with dosing flexibility that branded products may not provide. The 503A standard requires pharmacy licensure, USP standards for sterility and quality, and prescriber oversight. PepScribe works exclusively with licensed 503A pharmacies. No hidden overseas supply chain.

Frequently asked questions